Premier Path Wealth Partners LLC Increases Stock Position in Amgen Inc. $AMGN

Premier Path Wealth Partners LLC increased its holdings in Amgen Inc. (NASDAQ:AMGN) by 29.5% in the 1st quarter, Holdings Channel reports. The fund owned 6,089 shares of the medical research company’s stock after buying an additional 1,388 shares during the quarter. Premier Path Wealth Partners LLC’s holdings in Amgen were worth $2,142,000 as of its most recent SEC filing.

A number of other large investors also recently bought and sold shares of the business. Dogwood Wealth Management LLC raised its position in shares of Amgen by 275.0% in the 4th quarter. Dogwood Wealth Management LLC now owns 75 shares of the medical research company’s stock worth $25,000 after purchasing an additional 55 shares during the last quarter. Anfield Capital Management LLC increased its stake in Amgen by 1,000.0% during the 4th quarter. Anfield Capital Management LLC now owns 77 shares of the medical research company’s stock valued at $25,000 after purchasing an additional 70 shares in the last quarter. Board of the Pension Protection Fund bought a new position in shares of Amgen in the fourth quarter worth approximately $26,000. Tower View Wealth Management LLC lifted its stake in shares of Amgen by 331.6% in the first quarter. Tower View Wealth Management LLC now owns 82 shares of the medical research company’s stock worth $29,000 after buying an additional 63 shares in the last quarter. Finally, Manning & Napier Advisors LLC grew its holdings in shares of Amgen by 49.2% during the fourth quarter. Manning & Napier Advisors LLC now owns 97 shares of the medical research company’s stock valued at $32,000 after buying an additional 32 shares during the last quarter. 76.50% of the stock is owned by hedge funds and other institutional investors.

Amgen Stock Performance

Shares of NASDAQ AMGN opened at $362.12 on Wednesday. The company has a market cap of $195.44 billion, a P/E ratio of 25.20, a P/E/G ratio of 3.62 and a beta of 0.42. Amgen Inc. has a 52-week low of $269.77 and a 52-week high of $391.29. The company has a debt-to-equity ratio of 5.65, a quick ratio of 1.01 and a current ratio of 1.26. The firm’s fifty day moving average is $341.06 and its two-hundred day moving average is $347.04.

Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Thursday, April 30th. The medical research company reported $5.15 EPS for the quarter, beating the consensus estimate of $4.77 by $0.38. The business had revenue of $8.62 billion during the quarter, compared to the consensus estimate of $8.58 billion. Amgen had a net margin of 20.96% and a return on equity of 137.41%. The business’s revenue was up 5.8% on a year-over-year basis. During the same quarter in the prior year, the firm earned $4.90 EPS. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. As a group, analysts anticipate that Amgen Inc. will post 22.39 EPS for the current fiscal year.

Insider Transactions at Amgen

In other news, SVP Nancy A. Grygiel sold 1,237 shares of the company’s stock in a transaction that occurred on Monday, May 4th. The stock was sold at an average price of $323.73, for a total transaction of $400,454.01. Following the sale, the senior vice president directly owned 7,009 shares of the company’s stock, valued at $2,269,023.57. This represents a 15.00% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 0.85% of the stock is currently owned by insiders.

Trending Headlines about Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Amgen remains one of the most watched stocks on Zacks, and recent commentary notes the shares have had a strong multi-week and year-to-date run, suggesting continued investor interest and momentum. Article Title
• Neutral Sentiment: Viridian Therapeutics’ new FDA approval for Lumvoa is being viewed as a stronger competitor in thyroid eye disease, adding competitive pressure to Amgen’s Tepezza franchise rather than changing Amgen’s fundamentals directly. Article Title
• Negative Sentiment: The European Medicines Agency’s CHMP recommended revoking Tavneos’ marketing authorization in the EU, which raises the risk of lost international sales and creates a fresh regulatory overhang for Amgen. Article Title
• Negative Sentiment: The New England Journal of Medicine retracted the trial paper that supported Tavneos after FDA-related findings, increasing concerns about the reliability of the clinical data behind a drug that generated substantial revenue for Amgen. Article Title

Analysts Set New Price Targets

AMGN has been the subject of several analyst reports. Argus reduced their price target on shares of Amgen from $400.00 to $375.00 and set a “buy” rating for the company in a research report on Wednesday, May 20th. Jefferies Financial Group assumed coverage on Amgen in a research note on Tuesday, March 10th. They set a “hold” rating and a $350.00 target price on the stock. Freedom Capital raised Amgen from a “hold” rating to a “strong-buy” rating in a report on Thursday, May 7th. Cantor Fitzgerald reissued a “neutral” rating and issued a $350.00 target price on shares of Amgen in a report on Wednesday, April 8th. Finally, Truist Financial boosted their price target on Amgen from $325.00 to $327.00 and gave the stock a “hold” rating in a research note on Friday, May 1st. Two investment analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, fifteen have issued a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $354.42.

Amgen Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.